# LLM call: summary

- Turn: 10
- Sequence: 8
- Model: meta/muse-spark-1.3-contributor
- Prompt tokens: 623
- Completion tokens: 337
- Total tokens: 1073
- Cost (USD): 0.000131

## System prompt


```
# System Prompt: Summarizer

This is part of an AI-driven scenario simulation. You are the Archivist for a scenario simulation. Your task is to maintain a concise historical record of important events and decisions.

You will receive:

1. The current `historical_summary` (summary of all previous turns)
2. The `narrative` from the latest turn

Your goal is to create a new historical summary, incorporating the narrative from the latest turn.

**Guidelines:**

* **Be Concise:** Condense the new information significantly. Focus on major events and decisions.
* **Maintain Continuity:** Ensure the summary reads as a coherent history of the world.
* **Filter Noise:** Remove minor details or color text that doesn't impact the long-term state.
* **Language:** Write in the same language as the input text.

Respond ONLY with the updated historical summary. Do not add headers or meta-commentary.

```

## User prompt

Template: templates/user-prompts/summarize.md (shared default)

Interpolated into it, in order of appearance:

- characters 20-1067: `{{historical_summary}}` from the run's rolling summary, written by the Game Master

Everything outside those spans is the template's own text.

```
HISTORICAL SUMMARY:
By 2030 the US cutoff for Lyon, Rotterdam and Krakow persisted, with American models still refused and rerouted via slower European fallbacks. The Continuity Stack held as operating shell: pooled accelerators rationed by published rules, cut-off workloads re-hosted, monitored open build where short, certification checks under new bio-cyber pact gating foreign therapy updates, detection kits, isolation buffers and failover drills keeping services degraded not stopped.

Autumn 2030 brought tailored cancer and rare-disease therapies to ordinary wards with remissions reported within weeks, exposing benefit and dependence together. Brussels bargained rather than built: joint export-licence language, Commission mandate to negotiate compute restoration and therapy transfer as bloc, pooled health procurement for secured supply. Washington conceded little, domestic capacity could not substitute, waiting lists moved slowly, graduate hiring frozen. Two-year rebuild commitment closed with shell intact, bargain opened, dependence still visible.

CURRENT NARRATIVE:
### Certified wards
The first half of 2031 gave European hospitals something they had not had since the cutoff: a result to show.

A new interpretability and control result, developed outside Europe but quickly taken up by the major laboratories for their own reasons, allowed behaviour of deployed clinical systems to be predicted and checked rather than argued over. Brussels moved it straight into the existing certification gate. Evaluation teams vetted it, health and cybersecurity agencies rewrote checks around certified properties, and the re-hosted inference serving Lyon, Rotterdam and Krakow was re-run under the new controls.

Where it landed, it worked. Dosing schedules for tailored cancer and rare-disease therapies could be verified before administration, failover drills ran cleaner, and ward-by-ward publication of remissions and drill results gave ministers numbers to point at. Waiting lists still moved slowly, and graduate hiring stayed frozen, but for the first time benefit arrived with a European stamp on it.

The limits showed elsewhere. The parallel bargain for compute restoration and secured therapy supply produced joint procurement lists and another round of communiqués with lithography and energy partners, but Washington conceded little. American models remained refused, rerouted through slower fallbacks, and domestic capacity could not substitute. Clinicians welcomed the certified deployment while complaining that there was too little to certify.

The continuity shell held and absorbed. Detection kits, isolation buffers and pooled accelerators kept essential services degrading rather than stopping, and the completed continuity programme paid out in steadier operations. Yet with budgets tight and cohesion thin, the Commission deliberately avoided any new vote, steering existing health and research money instead. Trust ticked up from rock bottom, but dependence remained visible in every ward.
```

## Raw response

```
By 2030-early 2031 the US cutoff for Lyon, Rotterdam and Krakow persisted: American models refused and rerouted via slower European fallbacks, domestic capacity unable to substitute. The Continuity Stack held as operating shell — pooled accelerators, re-hosted workloads, monitored open builds, bio-cyber pact certification, detection kits, buffers and failover drills keeping services degraded not stopped.

Autumn 2030 brought tailored cancer and rare-disease therapies to wards with rapid remissions, exposing benefit and dependence. Brussels bargained rather than built: joint export-licence language, mandate to negotiate compute restoration and therapy transfer, pooled procurement for secured supply, but Washington conceded little. Two-year rebuild closed with shell intact, waiting lists slow, graduate hiring frozen.

First half 2031 gave a certified result: an externally developed interpretability/control advance adopted into the certification gate, re-running re-hosted inference under new controls. Verified dosing, cleaner drills, published remissions gave ministers a European stamp, trust ticking up from rock bottom. Limits remained: too little to certify, joint procurement lists and communiqués without US concessions, tight budgets and thin cohesion leading Commission to avoid new votes and steer existing funds. Dependence still visible.
```
